ArticleBritish journal of cancer2005
Interleukin-1 receptor antagonist haplotype associated with prostate cancer risk.
Article in British journal of cancer, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 55 citations in OpenAlex.
- Single-Cell Landscape of Bronchoalveolar Lavage Fluid Identifies Specific Neutrophils during Septic Immunosuppression.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- The association between waist-to-height index and prostate cancer risk: evidence from the NHANES study.Frontiers in nutrition · 2025Article
- Review
- The Role of Interleukin-1-Receptor-Antagonist in Bladder Cancer Cell Migration and Invasion.International journal of molecular sciences · 2021Article
- Blood-Derived Biomarkers of Diagnosis, Prognosis and Therapy Response in Prostate Cancer Patients.Journal of personalized medicine · 2021Review
- NFκB-Mediated Invasiveness in CD133Molecular cancer research : MCR · 2018Article
- Article
- IL1RN and KRT13 Expression in Bladder Cancer: Association with Pathologic Characteristics and Smoking Status.Advances in urology · 2014Article
- IL-1RN VNTR polymorphism and genetic susceptibility to cervical cancer in Portugal.Molecular biology reports · 2012Article
- Association of the innate immunity and inflammation pathway with advanced prostate cancer risk.PloS one · 2012Article
- Article
- Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence.Cancer immunology, immunotherapy : CII · 2011Article
- Inflammatory genetic markers of prostate cancer risk.Cancers · 2010Article
- Polymorphisms of pro-inflammatory genes and prostate cancer risk: a pharmacogenomic approach.Cancer immunology, immunotherapy : CII · 2009Review
- C-reactive protein haplotype is associated with high PSA as a marker of metastatic prostate cancer but not with overall cancer risk.British journal of cancer · 2009Article
- The prognostic value of four interleukin-1 gene polymorphisms in Caucasian women with breast cancer: a multicenter study.BMC cancer · 2009Article
- Serum levels of interleukin-1 receptor antagonist (IL-1ra) in thyroid cancer patients.Langenbeck's archives of surgery · 2008Article
- Inflammation in prostate carcinogenesis.Nature reviews. Cancer · 2007Review
- Interleukin gene polymorphisms and breast cancer: a case control study and systematic literature review.BMC cancer · 2006Article
- Using high-throughput SNP technologies to study cancer.Oncogene · 2006Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IL1-RN is an important anti-inflammatory cytokine that modulate the inflammation response by binding to IL1 receptors, and as a consequence inhibits the action of proinflammatory cytokines IL1alpha and IL1beta. In this study, we hypothesise that sequence variants in the IL1-RN gene are associated with prostate cancer risk. The study population, a population-based case-control study in Sweden, consisted of 1383 prostate cancer case patients and 779 control subjects. We first selected 18 sequence variants covering the IL1-RN gene and genotyped these single-nucleotide polymorphisms (SNPs) in 96 control subjects. Gene-specific haplotypes of IL1-RN were constructed and four haplotype-tagging single-nucleotide polymorphisms (htSNPs) were identified (rs878972, rs315934, rs3087263 and rs315951) that could uniquely describe >95% of the haplotypes. All study subjects were genotyped for the four htSNPs. No significant difference in genotype frequencies between cases and controls were observed for any of the four SNPs based on a multiplicative genetic model. Overall there was no significant difference in haplotype frequencies between cases and controls; however, the prevalence of the most common haplotype (ATGC) was significantly higher among cases (38.7%) compared to controls (33.5%) (haplotype-specific P = 0.009). Evaluation of the prostate cancer risk associated with carrying the 'ATGC' haplotype revealed that homozygous carriers were at significantly increased risk (odds ratio (OR) = 1.6, 95% confidence interval (CI) = 1.2-2.2), compared to noncarriers, while no significant association was found among subjects heterozygous for the haplotype (OR = 1.0, 95% CI = 0.8-1.2). Restricting analyses to advanced prostate cancer strengthened the association between the 'ATGC' haplotype and disease risk (OR for homozygous carriers vs noncarriers 1.8, 95% CI = 1.3-2.5). In conclusion, the results from this study support the hypothesis that inflammation has a role of in the development of prostate cancer, but further studies are needed to identify the causal variants in this region and to elucidate the biological mechanism for this association.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.